Skip to main content
All lobbying filings

FIERCE GOVERNMENT RELATIONS

FIERCE GOVERNMENT RELATIONS filed a Q2 report for ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) on July 21, 2025, reporting $60,000 in lobbying income.

Lobbying for ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) · Trade Organization for Generic Drug Manufacturers and Distributers

All filings by FIERCE GOVERNMENT RELATIONS · Everything ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 21, 2025
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 1
  • PATRICK CLIFTON New on this filing
    Previously held: Special Asst. to the President for Operations, Executive Office of the President, President Donald J. Trump (17-19).

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1
Pharmacy

Supply Chain, Drug Shortages, Tariffs, Patent Thickets, S.1041 - Affordable Prescriptions for Patients Act, S.43 - Skinny Labels - Big Savings Act, S.1302 - A Bill to Provide for Increased Transparency in Generic Drug Applications, S.1954- Biosimilar Red Tape Reduction Act, S.1414 - Expected Access to Biosimilars Act, Access to Biosimilars, Generic Manufacturing Marketplace Issues

 Bills named in this filing 5
  • S. 1041
    Affordable Prescriptions for Patients Act
  • S. 43
    Skinny Labels, Big Savings Act
  • S. 1302
    Increasing Transparency in Generic Drug Applications Act
  • S. 1954
    Biosimilar Red Tape Elimination Act
  • S. 1414
    Expedited Access to Biosimilars Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem